FDA Inspection 1280338 — Nipro Renal Soultions USA, Corporation

Nipro Renal Soultions USA, Corporation — FEI 1000142899

The FDA completed an inspection of Nipro Renal Soultions USA, Corporation on March 27, 2026 in Lewisberry, PA. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). 15 citations were issued during this inspection. Product area: Devices.

Inspection Details

Classification
Official Action Indicated (OAI) (OAI)
End Date
March 27, 2026
Fiscal Year
2026
Product Type
Devices
Project Area
Compliance: Devices
Location
Lewisberry, PA (United States)

Citations

IDCFRDescription
23019ISO 13485:2016 Clause 4.1.2Risk-based approach not applied to QMS processes
23036ISO 13485:2016 Clause 4.2.3Medical device file not established and maintained
23078ISO 13485:2016 Clause 6.3Maintenance records not maintained
23080ISO 13485:2016 Clause 6.4.1Work environment requirements and procedures not documented
23130ISO 13485:2016 Clause 7.3.9Procedures to control design and development changes not documented
23136ISO 13485:2016 Clause 7.3.10Design and development files not maintained
23142ISO 13485:2016 Clause 7.4.1Supplier performance not monitored
23157ISO 13485:2016 Clause 7.5.1Medical device or batch records not adequate
23174ISO 13485:2016 Clause 7.5.6Records of validation of processes and necessary actions not maintained
23219ISO 13485:2016 Clause 8.2.2Complaint handling records not maintained
23220ISO 13485:2016 Clause 8.2.4Internal audits not conducted to ensure QMS meets requirements and is effective
23231ISO 13485:2016 Clause 8.2.6Evidence of conformity to the acceptance criteria not maintained
23236ISO 13485:2016 Clause 8.3.1Nonconforming product not identified and controlled
23239ISO 13485:2016 Clause 8.3.1Records of nonconforming product and actions taken not maintained
23255ISO 13485:2016 Clause 8.5.2Corrective action not taken